Given the varying levels of success as well as acceptable safety profile yielded by anti-EpCAM antibody therapeutics, anti-EpCAM chimeric antigen receptors (CAR) have been developed to modify natural killer (NK) cells and T cells to kill EpCAM-expressing prostate cancer cells and breast carcinoma cells [18–24]. The gene discussed is EPCAM; the disease is prostate carcinoma.